Loading...

The current price of PBM is 1.48 USD — it has decreased -6.33 % in the last trading day.
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Wall Street analysts forecast PBM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Psyence Biomedical Ltd revenue for the last quarter amounts to -1.51M USD, increased 30.18 % YoY.
Psyence Biomedical Ltd. EPS for the last quarter amounts to -251456.00 USD, decreased % YoY.
Psyence Biomedical Ltd (PBM) has 12 emplpoyees as of December 16 2025.
Today PBM has the market capitalization of 2.77M USD.